The pharmaceuticals and chemicals sector is among the largest on the Dhaka Stock Exchange by market capitalization, with a combined market cap exceeding BDT 50,000 crore as of early 2026. For investors studying the DSE pharma sector, the numbers tell a story of steady domestic growth, an accelerating export push, and a looming structural shift tied to Bangladesh’s LDC graduation.
This overview covers the sector’s weight, major listed companies, export trajectory, the TRIPS compliance question, and the risks worth watching.
Sector Weight and Scale
The DSE lists more than 30 companies under the Pharmaceuticals and Chemicals category. Square Pharmaceuticals alone accounts for roughly 5.6% of total DSE market capitalization. With an estimated market cap of BDT 20,370 crore as of late 2025, it ranks among the two or three largest companies on the exchange.
Pharmaceuticals is consistently one of the top three sectors by market cap weight on the DSEX, alongside banking and telecom. The sector P/E ratio stood at approximately 10.2x as of late 2025, below its three-year average of 14.5x. The compression suggests the market is pricing in uncertainty around LDC graduation and regulatory changes.
Key Listed Pharma Companies
The table below summarizes the largest DSE-listed pharmaceutical companies based on the most recently available public data.
| Company | Ticker | Approx. Market Cap (BDT Cr) | FY2025 Revenue (BDT Cr) | P/E (Approx.) | Dividend Yield |
|---|---|---|---|---|---|
| Square Pharmaceuticals | SQURPHARMA | ~20,370 | ~7,629 | ~15x | ~3.0% |
| Beximco Pharmaceuticals | BXPHARMA | ~6,800 | ~4,700 | ~10x | ~3.8% |
| Renata Limited | RENATA | ~9,400 | ~4,200 | ~22x | ~1.5% |
| ACI Limited | ACI | ~2,800 | ~3,500 | ~12x | ~2.0% |
| ACME Laboratories | ACMELAB | ~3,500 | ~2,800 | ~14x | ~2.5% |
Data compiled from DSE filings, annual reports, and financial data providers. Figures are approximate and reflect the most recently available reporting periods. Investors should verify current figures on dsebd.org.
Square Pharmaceuticals is the sector leader by both market cap and profitability. In the January–March 2025 quarter, Square reported revenue of BDT 2,013 crore and net profit of BDT 605 crore — a 22% and 23% year-on-year increase respectively. Renata has consistently posted strong earnings growth, with a 26% profit increase in its most recent full year.
The Export Growth Story
Bangladesh’s pharmaceutical industry meets approximately 98% of domestic demand for finished-form drugs. The real growth story, however, is exports.
- FY2024–25 export trajectory: Pharma exports reached approximately USD 177 million in the first ten months of FY2024–25, a 3.5% year-on-year increase.
- Target: The industry is projected to exceed USD 225 million in annual exports by end-2025, with a longer-term goal of USD 1 billion by 2029–30.
- Markets: Bangladeshi generics are exported to over 160 countries, with growing presence in CIS nations, Sub-Saharan Africa, and Latin America.
The shift from exporting finished dosage forms toward manufacturing Active Pharmaceutical Ingredients (APIs) is the next critical phase. The 200-acre API Industrial Park in Gazaria, Munshiganj, has 27 companies setting up manufacturing plants, with production expected to begin in 2026.
LDC Graduation: The Structural Shift
Bangladesh is scheduled to graduate from Least Developed Country (LDC) status on November 24, 2026. This is arguably the single most important structural event for the DSE pharma sector.
What changes after graduation:
- TRIPS compliance becomes mandatory. Bangladesh currently benefits from a WTO waiver that allows local manufacturers to produce patented drugs without paying royalties. After LDC graduation, this waiver ends.
- New drug registrations affected. Over 1,000 applications for generic and biosimilar drugs are reportedly pending with the Directorate General of Drug Administration (DGDA), as companies race to register products before the waiver expires.
- Cost implications. Studies, including one by the Geneva-based South Centre, have estimated that prices for certain drugs (such as insulin) could rise significantly — potentially several-fold — without the TRIPS waiver.
Companies that have invested in original molecule development, API backward integration, and international regulatory compliance (FDA/EU-GMP) are better positioned for the post-LDC environment. Square Pharmaceuticals and Beximco Pharmaceuticals have both made investments in API manufacturing and international certifications.
Sector Risks
Investors analyzing Bangladesh pharmaceutical stocks should consider these risk factors:
-
Raw material import dependency. Bangladesh imports approximately 85–97% of its Active Pharmaceutical Ingredients, primarily from China and India. The annual API import bill is roughly USD 1.3 billion. Currency depreciation or supply chain disruptions in source countries directly affect margins.
-
Regulatory risk. Drug pricing in Bangladesh is regulated by the DGDA. Policy changes on pricing, import duties on raw materials, or registration requirements can affect profitability across the sector.
-
Post-LDC margin compression. Royalty payments on patented molecules after TRIPS compliance will increase costs. Companies without diversified portfolios or API manufacturing capability face the greatest pressure.
-
Currency and repatriation risk. Export revenues are USD-denominated, but costs are partly in BDT. Exchange rate movements affect reported earnings.
What to Watch
- API Park production timelines. Whether the Munshiganj API Industrial Park begins commercial production on schedule in 2026 will signal the sector’s readiness for backward integration.
- DGDA registration pipeline. The pace at which pending drug registrations are processed before the November 2026 LDC graduation deadline.
- Sector P/E re-rating. At approximately 10x earnings, the sector trades below its historical average. Whether this reflects a buying opportunity or appropriate risk pricing depends largely on how smoothly the TRIPS transition unfolds.
- Export growth trajectory. Quarterly export figures from the Export Promotion Bureau will indicate whether the USD 1 billion target by 2030 remains realistic.
The DSE pharma sector combines a defensive domestic business (healthcare demand is relatively recession-resistant) with an export growth optionality that few other sectors on the exchange can match. The LDC graduation transition introduces genuine uncertainty, but it also separates companies with durable competitive advantages from those reliant on regulatory shelter.
This content is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Past performance does not guarantee future results. Consult a BSEC-registered financial advisor before making investment decisions.